These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19022808)

  • 1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
    Furst DE; Keystone EC; Kirkham B; Kavanaugh A; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Burmester GR; Braun J; Emery P; Winthrop K; Bresnihan B; De Benedetti F; Dörner T; Gibofsky A; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii2-25. PubMed ID: 19022808
    [No Abstract]   [Full Text] [Related]  

  • 2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
    Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216
    [No Abstract]   [Full Text] [Related]  

  • 3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Sieper J; Emery P; Keystone EC; Schiff MH; Mease P; van Riel PL; Fleischmann R; Weisman MH; Weinblatt ME
    Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
    [No Abstract]   [Full Text] [Related]  

  • 5. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
    Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i2-45. PubMed ID: 22460137
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
    Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
    [No Abstract]   [Full Text] [Related]  

  • 7. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
    Furst DE; Keystone EC; So AK; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Rubbert-Roth A; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop KL
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii2-34. PubMed ID: 23532441
    [No Abstract]   [Full Text] [Related]  

  • 8. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Bijlsma JW; Burmester GR; Cronstein B; Keystone EC; Kavanaugh A; Klareskog L
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii2-7. PubMed ID: 12379612
    [No Abstract]   [Full Text] [Related]  

  • 9. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 11. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
    Wollenhaupt J; Krüger K
    Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in rheumatoid arthritis.
    Köller MD
    Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapies for treatment of rheumatoid arthritis.
    Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
    Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with biologics of pregnant patients with rheumatic diseases.
    Ostensen M; Förger F
    Curr Opin Rheumatol; 2011 May; 23(3):293-8. PubMed ID: 21346578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putting new disease-modifying antirheumatic drugs into perspective.
    Saseen JJ
    Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.